- 15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
- 7 April 2021SV NewsThe Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio
- 17 March 2021Portfolio NewsAmathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases
- 16 March 2021Portfolio NewsAlchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
- 2 February 2021Portfolio NewsQurAlis Continues to Expand Leadership Team with Two Key Hires
- 6 January 2021Portfolio NewsRibometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics
- 18 November 2020Portfolio NewsCaraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease
- 16 November 2020Portfolio NewsCerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study
- 12 November 2020Portfolio NewsNitrome Biosciences Announces Formation of Scientific Advisory Board and Appointment of Former AbbVie Executive James Summers, Ph.D. to SAB Chairperson
- 28 September 2020Portfolio NewsQurAlis named as one of Fierce Biotech's 2020 Fierce 15
- 22 July 2020Portfolio NewsExcellent news today from our portfolio company @Cerevance on the expansion of its Series B financing round, adding a further $20 million to the $45 million announced in April.
- 1 July 2020Portfolio NewsQurAlis Announces Agreement to Strengthen ALS Pipeline